Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 24:9:966331.
doi: 10.3389/fcvm.2022.966331. eCollection 2022.

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system

Ziyang Wu  1   2 , Pengxiang Zhou  1   2 , Na He  1   2 , Suodi Zhai  1   2
Affiliations

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system

Ziyang Wu et al. Front Cardiovasc Med. .

Abstract

Objective: This study aimed to identify the most common and top drugs associated with the risk of torsades de pointes (TdP) based on the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.

Materials and methods: We used OpenVigil 2.1 to query FAERS database and data from the first quarter of 2004 to the third quarter of 2021 were retrieved. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify TdP cases. We listed the most common drugs associated with the reported TdP cases. Then, the reporting odds ratio (ROR) and the proportional reporting ratio (PRR) for the reporting association between different drugs and TdP risk were calculated. Meanwhile, comparisons were conducted with the QT drug lists of CredibleMeds® in an attempt to identify drugs with a potential risk of TdP that were not on the list.

Results: A total of 9,217,181 adverse event reports were identified, of which 3,807 (0.04%) were related to TdP. TdP was more likely to occur in the elderly and females. Amiodarone (464 cases) was associated with most cases of TdP. According to the disproportionality analysis, the top five drugs with the highest ROR and PRR were tolazoline (ROR 1615.11, 95% confidence interval [CI] 455.59-5725.75, PRR 969.46, χ2 2960.10), levomethadyl (ROR 1211.01, 95% CI 302.75-4844.04, PRR 807.67, χ2 1677.03), ibutilide (ROR 1118.74, 95% CI 425.00-2944.91, PRR 765.77, χ2 3845.27), halofantrine (ROR 660.55, 95% CI 184.21-2368.69, PRR 519.22, χ2 1076.31), and isoproterenol (ROR 352.20, 95% CI 227.19-546.00, PRR 307.82, χ2 6692.53). Approximately half of the top 50 drugs (22 for ROR, 30 for PRR) were not outlined on the QT drug lists of CredibleMeds®.

Conclusion: Approximately half of the top risk drugs (22 for ROR, 30 for PRR) were not outlined in the QT drug lists of CredibleMeds®. Notably, potential risks are of great importance and should be closely monitored in clinical practice. Also, further research is needed to investigate the association between these drugs and TdP.

Keywords: FAERS; disproportionality analysis; long QT syndrome; pharmacovigilance; torsades de pointes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor FS declared a shared affiliation with the authors at the time of review.

Figures

FIGURE 1
FIGURE 1
Top 50 drugs with the most number of cases of TdP. The vertical axis is the name of the drugs, and the horizontal axis is the corresponding number of cases of TdP for each drug. The orange color represents that the drug is included on the QT drug lists of CredibleMeds®. The yellow color represents that the drug is not included on the QT drug lists of CredibleMeds®.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Li S, Xu Z, Guo M, Li M, Wen Z. Drug-induced QT prolongation atlas (DIQTA) for enhancing cardiotoxicity management. Drug Discov Today. (2022) 27:831–7. 10.1016/j.drudis.2021.10.009 - DOI - PubMed
    1. Novotný T. Mechanisms and Incidence of Torsades de Pointes Tachycardia. Sex and Cardiac Electrophysiology. London: Academic Press; (2020). p. 303–8.
    1. Molokhia M, Pathak A, Lapeyre-Mestre M, Caturla L, Montastruc JL. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France. Br J Clin Pharmacol. (2008) 66:386–95. 10.1111/j.1365-2125 - DOI - PMC - PubMed
    1. Vandael E, Vandenberk B, Vandenberghe J, Pincé H, Willems R, Foulon V. Incidence of torsade de pointes in a tertiary hospital population. Int J Cardiol. (2017) 243:511–5. 10.1016/j.ijcard.2017.05.072 - DOI - PubMed
    1. Shah RR. Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter? Br J Clin Pharmacol. (2013) 75:347–58. 10.1111/j.1365-2125.2012.04415.x - DOI - PMC - PubMed

LinkOut - more resources